NEXGEL (NXGL) said Monday it is expanding its collaboration with European consumer health company STADA Arzneimittel to launch new digestive enzyme formulas and products for scars and stretch marks.

As part of the deal, STADA will provide NEXGEL with $1 million in non-dilutive funding to support product launches and marketing efforts, the company said.

Shares of NEXGEL were down 1.5% in recent Monday trading.

Price: 2.65, Change: -0.04, Percent Change: -1.48